Dr Sara Ballester's first research focused on the DNA replication and antibiotic resistance of gram-positive bacteria and described a mechanism to generate resistance to antibiotics through the replication machinery of bacterial plasmids. Afterwards, she focused on T cell activation. She found differences between Th1 and Th2 cells during NFkB activation and characterised the proximal promoter of the IL-4Ra gene. She also described a negative control mechanism of IL-4 expression through Stat6. Later, her work on T cells related to the problem of multiple sclerosis. She analysed the activation statuses of NFkB and AP-1 in the T cells of patients with MS. She explored therapeutic agents for the disease in the EAE animal model and the mechanisms of its effects and described several effects on the activity of T cells by IFNb treatments or by the inhibition of PDE, obtaining a patent for an inhibitory molecule of PDE7 with therapeutic potential for multiple sclerosis, which prevents cell infiltration and inflammation in the CNS. Her team has demonstrated the anti-inflammatory effects of decidua mesenchymal stem cells in the EAE model. The treatment restrains inflammatory infiltration by Th17 cells, monocytes and neutrophils. Lately, she has been interested in the influence of the Hedgehog pathway on the immune response. In collaboration with Dr Gallego, who has experience in this signalling pathway, the team has analysed the effects of its overactivation during EAE.
Dr Sara Ballester's first research focused on the DNA replication and antibiotic resistance of gram-positive bacteria and described a mechanism to generate resistance to antibiotics through the replication machinery of bacterial plasmids. Afterwards, she focused on T cell activation. She found differences between Th1 and Th2 cells during NFkB activation and characterised the proximal promoter of the IL-4Ra gene. She also described a negative control mechanism of IL-4 expression through Stat6. Later, her work on T cells related to the problem of multiple sclerosis. She analysed the activation statuses of NFkB and AP-1 in the T cells of patients with MS. She explored therapeutic agents for the disease in the EAE animal model and the mechanisms of its effects and described several effects on the activity of T cells by IFNb treatments or by the inhibition of PDE, obtaining a patent for an inhibitory molecule of PDE7 with therapeutic potential for multiple sclerosis, which prevents cell infiltration and inflammation in the CNS. Her team has demonstrated the anti-inflammatory effects of decidua mesenchymal stem cells in the EAE model. The treatment restrains inflammatory infiltration by Th17 cells, monocytes and neutrophils. Lately, she has been interested in the influence of the Hedgehog pathway on the immune response. In collaboration with Dr Gallego, who has experience in this signalling pathway, the team has analysed the effects of its overactivation during EAE.